F. Hoffmann-La Roche AG
Pharmaceuticals and DiagnosticsFounded 1896- Updated June 2025
Reviewed by Swet Parvadiya
Last reviewed: June 2025
CorpDigest
F. Hoffmann-La Roche AG
Founders
Fritz Hoffmann-La Roche · Founded 1896 · Basel, Switzerland
Last reviewed: June 2025 · By Swet Parvadiya
Quick Answer
F. Hoffmann-La Roche AG was founded by Fritz Hoffmann-La Roche in 1896 in Basel, Switzerland. The company is currently led by Thomas Schinecker.
Fritz Hoffmann-La Roche established the company in Basel in 1896 with a specific thesis: that standardized pharmaceutical manufacturing could replace the variable-quality preparations dispensed by individual pharmacists. The idea that a drug should have predictable potency and consistent composition was not universally accepted in 1896 — it was a business model and a public health argument simultaneously. The company's early success with products like Thiocol for tuberculosis and Digalen for heart conditions established the brand as a provider of reliable, measurable medicines.
The Basel location was not accidental. Switzerland's political neutrality, its proximity to German pharmaceutical chemistry, and its banking secrecy made it the natural home for pharmaceutical manufacturers who needed to operate across European borders without entanglement in nationalist trade barriers. Roche shared the Baselarea with Novartis, Ciba, and Sandoz — a pharmaceutical concentration that made Switzerland the per-capita pharmaceutical R&D leader in the world.
The twentieth century at Roche was defined by the discovery of Valium and Librium in the 1960s, which became the bestselling pharmaceuticals in the world and generated the cash flows that funded the company's subsequent expansion into diagnostics and oncology. The acquisition of a majority stake in Genentech, the San Francisco biotechnology pioneer, and eventual full acquisition in 2009 gave Roche access to monoclonal antibody technology that became the foundation for its oncology portfolio — Herceptin, Avastin, and MabThera — the drugs that defined the company's revenue profile for a decade.
Thomas Schinecker
Chief Executive Officer
Thomas Schinecker became Roche CEO in March 2023, succeeding Severin Schwan. He has focused on strengthening Roche’s pharmaceutical pipeline in oncology, neurology, and rare diseases while navigating post-COVID revenue normalization.
Severin Schwan
Former Chief Executive Officer
Severin Schwan led Roche for over a decade, overseeing the company’s growth to CHF 63.3 billion in revenue (2019 peak), major oncology drug launches including Tecentriq and Hemlibra, and the $1.7 billion Foundation Medicine acquisition.
Fritz Hoffmann-La Roche was born on October 24, 1868 in Basel, Switzerland into a Basel commercial family with banking and trading interests. He attended commercial school and trained as a businessman rather than as a scientist or chemist. In 1893 he married Adele La Roche, the daughter of another prominent Basel family, and adopted her surname alongside his own, a not uncommon Basel practice. After working in his father's bank and in chemical trading, the 28-year-old Hoffmann founded F. Hoffmann-La Roche & Co. on October 1, 1896 with a chemical-trader partner who departed within months, leaving Hoffmann as the sole proprietor. The early business focused on the industrial production of standardized pharmaceutical preparations, an early bet on the transition from compounding pharmacies to branded mass-market drugs. Hoffmann was a businessman with an instinct for international expansion; by 1914, just eighteen years after founding, Roche operated subsidiaries in nine countries on three continents. He died on April 18, 1920 at age 51, leaving the company to his family. The Roche company continues to bear his name and the unusual hyphenated surname is preserved in the corporate identity more than 125 years later.
The Hoffmann, Oeri, and Duschmalé families are descendants of founder Fritz Hoffmann-La Roche through his daughter Maja Hoffmann, who married Theophil Oeri in 1922; further intermarriages produced the Duschmalé branch. The family members hold their Roche bearer shares (Inhaberaktien) inside a pooled shareholder agreement that requires unanimity for transfers outside the family and binds the members to vote their shares as a bloc. The pool collectively holds roughly 50 percent of Roche's voting power despite owning a much smaller share of total economic value, somewhere in the 9 to 11 percent range when accounting for the non-voting Genussscheine. The most public family member is Andre Hoffmann, a great-grandson of the founder, who serves as Vice Chairman of the Roche Board and is also the chairman of the Hoffmann family's holding entities. Vera Michalski-Hoffmann, his sister, has a more philanthropic and arts-focused public profile. The family preserves control by treating Roche as a multi-generational steward rather than a tradable asset, by avoiding public family disputes, and by working closely with non-family management through a structured governance arrangement that has been remarkably stable for more than 125 years.
Fritz Hoffmann-La Roche's early strategic decisions established the architecture of the modern company more than a century after his death. He recognized that the pharmaceutical market was shifting from local compounding pharmacies to standardized branded preparations and committed Roche to industrial-scale manufacturing of consistent products under brand names rather than generic chemical sales. He invested heavily in advertising and physician marketing, an unusual practice for the late nineteenth century when most drugs were sold without consumer or prescriber promotion. He pursued international expansion aggressively, opening subsidiaries in Italy (Milan), the United States (New York), the United Kingdom (London), France (Paris), Russia (St. Petersburg), and Japan (Yokohama) within fifteen years of founding. He focused the early portfolio on standardized products with clear therapeutic claims: Sirolin for cough, Pantopon for pain, thyroid preparations for hypothyroidism. The combination of industrial manufacturing, branded marketing, and international distribution became the template for modern pharmaceutical companies. Hoffmann did not live to see the company's later expansion into biologics or the Genentech era, but the multinational orientation he installed in the first two decades has persisted continuously through more than 125 years of operations.
Fritz Hoffmann-La Roche died on April 18, 1920 at age 51, leaving the company in the hands of his family and a senior management team led by Emil Christoph Barell, the long-time managing director who had joined Roche in 1898 as a young chemist. Barell led the company through the interwar period, the Great Depression, and the Second World War, eventually serving as chairman until his death in 1953. Under Barell, Roche industrialized the synthesis of vitamins (work that earned chemist Tadeus Reichstein the 1950 Nobel Prize in Medicine) and built the foundations of the modern pharmaceutical portfolio. The Hoffmann family retained voting control throughout, supported by the pooled shareholder agreement that has remained in continuous operation for more than a century. The family also weathered the wartime period without losing its grip on the company despite the Second World War's disruption of European pharmaceutical markets. The continuity from Fritz Hoffmann-La Roche through Barell through subsequent professional managers including Adolf Jann, Fritz Gerber, Franz Humer, Severin Schwan, and Thomas Schinecker is one of the longest unbroken corporate leadership lineages in global pharmaceuticals.